MENU
FEB 07, 2017 6:00 AM PST

Heparin Monitoring: aPTT versus Anti-Xa assay

Sponsored by: Diagnostica Stago, Inc.
Speaker
  • QA Manager for Specialty Testing Supervisor, Special Coagulation and Hematology, New York Presbyterian Hospital
    Biography
      Donna is Quality Assurance (QA) Manager, Specialty Testing Supervisor, Special Coagulation and Special Hematology at New York Presbyterian Hospital- Columbia in New York City. She has 34 years clinical laboratory experience, 6 years industry clinical trial experience, including PhD work on Standardization of Laboratory Testing (all but dissertation). Donna has written several book chapters, many publications and presented many coagulation lectures to diverse audiences at all levels of expertise. She is adjunct professor at York College and Rutgers University. Donna presently serves on the Executive Committee of the North American Specialized Coagulation Laboratory Association (NASCOLA) as a Secretary, Publication Committee and Pre-Curriculum Committee for the American Society for Clinical Pathology (ASCP), and the Expert Committee for Hematology for the Clinical Laboratory Standards Institute (CLSI). She is also a member of International Society on Thrombosis and Haemostasis (ISTH), International Society for Laboratory Hematology (ISLH) and ASCP.

    Abstract

    This webinar will look at the principles of the assays available to monitor heparin.  The most frequent assay that is used is the activated partial thromboplastin time (aPTT).  This assay is readily available and inexpensive.  However aPTT reagents are poorly standardized and have different sensitivities to heparin. There is no dose response relationship with heparin.  Due to the analytical and biological variables of heparin, patients respond to it differently.  Laboratories using the aPTT to monitor heparin, need to provide clinicians with a heparin therapeutic range specific for their lot of reagent on their analyzer.  An anti-Xa assay is a standardized test that has good precision, and is linear. A heparin assay can provide clinicians with an assay that accurately determines heparin levels and can improve overall patient heparin management.

    The objectives of this webinar are:

    • Describe the principle of the aPTT and  heparin assays
    • Identify the advantages of each assay and outcomes for patient care
    • Enhance problem solving skills by analyzing data from case studies.

    Show Resources
    You May Also Like
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    Loading Comments...
    Show Resources
    Attendees
    • See more